Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po
Roche has paid $310 million upfront for rights to Alnylam Pharma's zilebesiran for hypertension, a handsome sum for a drug that so far has only generated phase 1 data.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh